<DOC>
	<DOCNO>NCT00464451</DOCNO>
	<brief_summary>The purpose study : 1 . To compare efficacy dexmedetomidine versus chloral hydrate pediatric sedation agent EEG study . Efficacy determine successful EEG study completion minimum degree sedation induce patient agitation ( SAS score ) . 2 . To compare safety adverse event profile dexmedetomidine versus chloral hydrate sedation pediatric patient EEG study . Comparison base variance vital sign ( HR , MAP , RR , O2SAT , ETCO2 ) baseline sedation well frequency adverse event follow sedation . 3 . To compare quality EEG recording obtain dexmedetomidine chloral hydrate non-sedated pediatric EEG study . Quality determine degree background beta-wave activity .</brief_summary>
	<brief_title>Dexmedetomidine Versus Chloral Hydrate Pediatric Sedation During EEG</brief_title>
	<detailed_description>Pediatric patient undergo EEG study often require sedation failure stay still record EEG ( difficulty obtain sleep state specific time procedure ) . The ideal sedation agent ( EEG ) rapid onset action , moderate duration effect , minimal absent side-effect profile minimal effect EEG quality . Historically , chloral hydrate oral agent choice sedate pediatric patient EEGs . However , chloral hydrate use fraught many problem sedation failure , drug-enhanced background beta-wave activity affect EEG quality , ( especially pediatric patient ) unpleasant intoxicated-like experience recover sedation . Uncommon specific adverse event associate use chloral hydrate include gastric irritation cause nausea , vomit , diarrhea ; residual sleepiness `` hangover '' ; rash , fever , dizziness , ataxia ; disorientation , paradoxical excitement , respiratory depression ( especially combine sedative narcotic ) . Side effect profile drug interference EEG quality chloral hydrate necessitates look alternate agent EEG sedation . Clonidine show well safety profile lack drug effect EEG quality Autistic child compare chloral hydrate . The beneficial effect clonidine ascribe alpha-2 receptor agonist activity . We believe new alpha-2 agonist dexmedetomidine well safety profile minimal effect EEG quality selective action alpha-2 receptor . Compared clonidine , dexmedetomidine specific alpha-2 receptor short elimination half-life . It produce dose-dependent sedation , anxiolysis analgesia without respiratory depression . Dexmedetomidine produce unusually cooperative form sedation , patient easily transition sleep wakefulness back sleep stimulate . Its use associate less disinhibition commonly associate sedation agent like propofol benzodiazepine . Hemodynamic effect dexmedetomidine result peripheral central mechanism ( peripheral vascular smooth muscle constriction , diminished central sympathetic outflow , increase vagal activity ) net result significant reduction circulate catecholamine , modest reduction blood pressure , modest reduction heart rate . Alpha-2 agonist show minimal effect ventilation healthy volunteer well ICU patient . The benign effect class drug ventilatory drive underscore approval dexmedetomidine FDA critical care sedative recommend continuous use extubation . Although alpha-2 agonist attenuate response stress , include neurohumoral response , short term use dexmedetomidine ( &lt; 24 hour ) significantly reduce serum cortisol level . Bioavailability study demonstrate dexmedetomidine well absorb systemically oral mucosa ( 82 % compare IV administration ) therefore , buccal dosing may provide effective , noninvasive route administer drug . Orally administer dexmedetomidine successfully utilized pre-medication pediatric procedural sedation anesthetic induction lessen anxiety psychological impact procedure dose range 1-4.2 micrograms/kg ( mean dose : 2.6 +/- 0.83 micrograms/kg ) . A large portion subject study neurobehavioral disorder spontaneously breathe , non-intubated patient . None subject experience clinically significant change cardiorespiratory parameter . Another study demonstrate successful sedation analgesia spontaneously breathe , non-intubated post-cardiothoracic surgery patient ( age 1 month 21 year age ) IV infusion dexmedetomidine . No significant change respiratory rate note . While several pediatric study explore use dexmedetomidine post-operative procedural sedation / analgesia child favorable result , currently approve FDA procedural sedation child . Uncommon specific adverse event associate use dexmedetomidine include hypertension , hypotension , bradycardia , tachycardia , nausea , vomit , fever , anemia , hypoxia . In summary , dexmedetomidine potential good sedative agent procedural non procedural sedation child , part favorable side-effect profile , minimal effect respiratory drive , minimal emergence agitation procedure . In addition , sublingual bioavailability make attractive alternate oral agent EEG sedation . It cause natural sleep ; child may intentionally arouse sedation resume sleep stimulate , allow complete EEG recording contain awake , drowsy sleep state . We hypothesize use dexmedetomidine sedation pediatric EEG study efficacious chloral hydrate superior safety profile , patient tolerance acceptance . We also hypothesize use dexmedetomidine minimize degree drug-enhanced background Beta-activity sedate EEG recording .</detailed_description>
	<mesh_term>Dexmedetomidine</mesh_term>
	<mesh_term>Chloral Hydrate</mesh_term>
	<criteria>1 . EEG study patient 2 . Age le 18 year 3 . No contraindication use chloral hydrate dexmedetomidine 1 . Active , uncontrolled Gastroesophageal Reflux Disease ( GERD ) 2 . Active , uncontrolled vomit 3 . Current history apnea require apnea monitor 4 . Active , current respiratory issue different baseline status 5 . Unstable cardiac status 6 . Craniofacial anomaly risk inadequate bagvalvemask ventilation 7 . Current use digoxin , betablockers , calcium channel blocker 8 . Current , active cerebral vascular disease 9 . Patient treat clonidine within precede one month 10 . Prior history drug reaction sedation failure either drug</criteria>
	<gender>All</gender>
	<minimum_age>4 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>